Vebreltinib Price Forecast 2025

Vebreltinib (vebreltinib) is a targeted drug that focuses on tumors driven by abnormal MET genes. It will usher in important domestic progress in 2025. The drug was independently developed and marketed in China in the form of bripretinib enteric-coated capsules, becoming the first domestically produced MET-TKI approved for the treatment of MET-mutated tumors. At present, it has been included in the national medical insurance directory, which undoubtedly reduces the treatment burden for patients with MET-mutated non-small cell lung cancer (NSCLC) and also reflects China's breakthrough in the field of precision tumor drug research and development.

The main indications of boricitinib include two major categories: one is locally advanced or metastatic non-small cell lung cancer (NSCLC) with stromal-epithelial transformation factor (MET) exon 14 skipping. This mutation causes overactivation of the MET protein, thereby promoting the growth and invasion of tumor cells. Bripretinib effectively inhibits tumor growth by selectively inhibiting MET tyrosine kinase activity and blocking downstream signaling pathways. The second is IDH mutant astrocytoma or progressive glioblastoma with PTPRZ1-MET fusion gene. This type of brain tumor has extremely limited treatment options, and bricitinib brings new treatment hope to these patients with its molecular structure that can penetrate the blood-brain barrier.

In terms of price, the current common specifications of bricitinib enteric-coated capsules are100mg × 60 capsules, with each box selling for about RMB 7,000. Since it has entered the scope of medical insurance, the patient's out-of-pocket payment ratio will be significantly reduced, and the actual treatment cost will be significantly reduced. According to the adjustment trend of medical insurance policies, there is still room for price reduction in the future. It is worth noting that there are currently no generic versions of bricitinib on the market.

From the perspective of the international market, bricitinib is still in the clinical trial stage in the United States, Europe and Japan, and has not yet achieved full commercial launch. Overseas pharmaceutical companies generally believe that the drug's positioning in the field of MET pathway inhibition is close to that of Capmatinib and Tepotinib, but it performs better in terms of central permeability and pharmacokinetic stability.

Reference materials:https://www.asymbio.com.cn/